PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-100.00%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-35.83%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
41.43%
Marketing expense growth while CRN.AX reduces spending. John Neff would investigate strategic advantage.
123.39%
Other expenses change of 123.39% while CRN.AX maintains costs. Bruce Berkowitz would investigate efficiency.
277.89%
Operating expenses growth while CRN.AX reduces costs. John Neff would investigate differences.
277.89%
Total costs growth while CRN.AX reduces costs. John Neff would investigate differences.
57010.74%
Interest expense change of 57010.74% while CRN.AX maintains costs. Bruce Berkowitz would investigate control.
71.91%
D&A growth while CRN.AX reduces D&A. John Neff would investigate differences.
3.13%
EBITDA growth 50-75% of CRN.AX's 6.09%. Martin Whitman would scrutinize operations.
100.00%
EBITDA margin growth while CRN.AX declines. John Neff would investigate advantages.
10.60%
Operating income growth while CRN.AX declines. John Neff would investigate advantages.
100.00%
Operating margin growth while CRN.AX declines. John Neff would investigate advantages.
-384.11%
Other expenses reduction while CRN.AX shows 71.85% growth. Joel Greenblatt would examine advantage.
-0.53%
Pre-tax income decline while CRN.AX shows 55.66% growth. Joel Greenblatt would examine position.
100.00%
Pre-tax margin growth exceeding 1.5x CRN.AX's 25.90%. David Dodd would verify competitive advantages.
-81.08%
Both companies reducing tax expense. Martin Whitman would check patterns.
13.84%
Net income growth below 50% of CRN.AX's 47.33%. Michael Burry would check for structural issues.
100.00%
Net margin growth exceeding 1.5x CRN.AX's 11.99%. David Dodd would verify competitive advantages.
23.33%
EPS growth below 50% of CRN.AX's 47.22%. Michael Burry would check for structural issues.
23.33%
Diluted EPS growth below 50% of CRN.AX's 47.31%. Michael Burry would check for structural issues.
16.66%
Share count increase while CRN.AX reduces shares. John Neff would investigate differences.
16.66%
Diluted share change of 16.66% while CRN.AX is stable. Bruce Berkowitz would verify approach.